Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Abiomed Inc (NQ: ABMD ) N/A UNCHANGED Last Price Updated: 4:00 PM EST, Dec 21, 2022 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Abiomed Inc < Previous 1 2 Next > FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial December 21, 2022 From Abiomed, Inc. Via Business Wire Can Pfizer, Johnson & Johnson Continue Outperforming the Index? December 09, 2022 Large-cap pharmaceuticals Pfizer and Johnson & Johnson are outperforming the broader market in the past year, particularly in the past three months. Via MarketBeat First Patients in the World Treated with Impella RP Flex with SmartAssist December 05, 2022 From Abiomed, Inc. Via Business Wire ABIOMED INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Abiomed, Inc. - ABMD November 16, 2022 From Kahn Swick & Foti, LLC Via Business Wire S&P 500 Component DexCom Set For Further Price, Earnings Growth November 13, 2022 Glucose monitor maker DexCom surged 19% after its Q3 report, and shares are holding those gains. Wall Street sees more growth ahead in 2023. Via MarketBeat Topics Stocks Exposures US Equities BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Oyster Point Pharma, Inc. (Nasdaq - OYST), Benefitfocus, Inc. (Nasdaq - BNFT), Abiomed, Inc. (Nasdaq - ABMD), Atlas Corp. (NYSE - ATCO) November 08, 2022 From Brodsky & Smith LLC Via GlobeNewswire ABIOMED INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Abiomed, Inc. - ABMD November 01, 2022 From Kahn Swick & Foti, LLC Via Business Wire Johnson & Johnson (NYSE: JNJ) Set to Acquire Abiomed (NASDAQ: ABMD) for $16.6 Billion or $380 per Share Plus CVR November 01, 2022 Abiomed, Inc. (NASDAQ: ABMD) is engaged as a medical technology company, which is focused on providing support and resources to Via Spotlight Growth Exposures Product Safety ABMD Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ABIOMED, Inc. Is Fair to Shareholders November 01, 2022 From Halper Sadeh LLC Via Business Wire Abiomed Announces Second Quarter Revenue of $266 Million, up 11% in Constant Currency*, up 7% on a Reported Basis Year Over Year November 01, 2022 From Abiomed, Inc. Via Business Wire Johnson & Johnson to Acquire Abiomed November 01, 2022 From Johnson & Johnson Via Business Wire Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure October 31, 2022 From Abiomed, Inc. Via Business Wire Abiomed Creates Patient Assistance Program to Address Disparities in Healthcare October 26, 2022 From Abiomed, Inc. Via Business Wire MedTechVets Appoints Patrice Sutherland, Enterprise Executive Director at Integra LifeScience, as New Board Chairperson October 24, 2022 From Abiomed, Inc. Via Business Wire Abiomed Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure October 20, 2022 From Abiomed, Inc. Via Business Wire U.S. FDA Grants 510(k) Clearance for Impella Low Profile Sheath October 17, 2022 From Abiomed, Inc. Via Business Wire Yale University Study Demonstrates Significant Survival Benefit in High-Risk PCI with Impella Support October 13, 2022 From Abiomed, Inc. Via Business Wire Abiomed Second Quarter Fiscal 2023 Earnings and Conference Call Notification October 13, 2022 From Abiomed, Inc. Via Business Wire Multi-Center, Multi-Society Study of Impella-supported Patients with Cardiogenic Shock due to Myocarditis in Japan Achieves 30-day Survival of 77% September 20, 2022 From Abiomed, Inc. Via Business Wire Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81% September 19, 2022 From Abiomed, Inc. Via Business Wire Unloading with Impella for 30 Minutes Before PCI Associated with Reduced Infarct Size in STEMI Patients September 17, 2022 From Abiomed, Inc. Via Business Wire FDA Approves RECOVER IV Randomized Controlled Trial with Exception from Informed Consent (EFIC) September 16, 2022 From Abiomed, Inc. Via Business Wire TCT 2022: Impella Enables Complete Revascularization, Improved Quality of Life and Native Heart Recovery September 13, 2022 From Abiomed, Inc. Via Business Wire Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella August 16, 2022 From Abiomed Via Business Wire ABIOMED Announces First Quarter Record Revenue of $277 Million, up 10% Year Over Year, up 12% in Constant Currency* August 04, 2022 From Abiomed, Inc. Via Business Wire Abiomed First Quarter Fiscal 2023 Earnings and Conference Call Notification July 14, 2022 From Abiomed, Inc. Via Business Wire Abiomed to Host Investor Call on Heart Failure Opportunity With Impella 5.5 and Impella BTR Heart Pumps June 14, 2022 From Abiomed, Inc. Via Business Wire Abiomed to Present (Live) at the William Blair 42nd Annual Growth Stock Conference May 31, 2022 From Abiomed, Inc. Via Business Wire SCAI 2022 Scientific Sessions Highlight Impella Research, Advancements to Improve Cardiogenic Shock Outcomes May 18, 2022 From Abiomed Via Business Wire Abiomed Announces Fourth Quarter Record Revenue of $270 Million, up 12% Year Over Year April 28, 2022 From Abiomed, Inc. Via Business Wire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.